Artiva Biotherapeutics, which had been evaluating cell therapy AlloNK for the treatment of rheumatoid arthritis and other ...
In the Phase 3 MagnetisMM-32 trial, ELREXFIO demonstrated a clinically meaningful and statistically significant benefit for ...
Third quarter revenue of $209 million, a year-over-year increase of 11% as reported and 12.5% organic Closed BioLife ...
(“NEXGEL” or the “Company”) (NASDAQ: NXGL), a company with a patient-centric medical technology sales and marketing team ...
Since its inception, The Confidence Collective has supported more than 500 women entrepreneurs and awarded more than $1.5 ...
Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines ...
Secures agreement pausing conversion rights until January 2027 (unless closing share price equals or exceeds $0.275) and ...
Third quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market ...
Q3 net sales grew +4% (cc ¹, +4% USD), with core operating income ¹ +10% (cc, +11% USD) Sales growth driven by priorit ...
Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) today announced that Azeem Latib, MD, ...
GOTHENBURG, SE / ACCESS Newswire / October 27, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company focused on ...
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results